Manufacturing of maytansinoid ADCs using ImmunoGen's technology relies on the attachment of the cytotoxic agent molecules (DM1 or DM4) via a linker to amino groups on antibodies. What is the best way to develop and implement the appropriate panel of analytical techniques?Session: Physicochemical Characterization of Maytansinoid ADCs
Speaker: Alex Lazar, Ph.D., Head of Analytical and Pharmaceutical Sciences, ImmunoGen, Inc.
Attend this session to learn about the development of an appropriate panel of analytical techniques for release and characterization of maytansinoid ADCs. Want to learn more about the particular challenges of ADC characterization for complex products comprising both an antibody and a chemically attached cytotoxic agent? Join us October 21-23 in Washington, D.C. at IBC's 17th Annual Well Characterized Biologicals event. To learn more, download our agenda.
As a reader of this blog, you’ll receive 15% off the standard rate when using code XB13193BLOG to register. We look forward to seeing you this fall!
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment